Valuation: Janux Therapeutics, Inc.

Market Cap 1.06B 947M 874M 793M 1.48B 100B 1.5B 10.48B 4.16B 52.54B 3.96B 3.88B 167B P/E 2026 *
-9.95x
P/E 2027 * -6.52x
Enterprise Value 156M 140M 129M 117M 219M 14.84B 222M 1.55B 616M 7.78B 586M 574M 24.66B EV / Sales 2026 *
5.31x
EV / Sales 2027 * 37.7x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day+3.42%
1 week+0.35%
Current month-0.12%
1 month+5.89%
3 months+10.85%
6 months+13.33%
Current year+25.07%
1 week 16.27
Extreme 16.27
17.63
1 month 16.13
Extreme 16.13
19.18
Current year 12.12
Extreme 12.12
20.31
1 year 12.12
Extreme 12.12
35.34
3 years 5.65
Extreme 5.65
71.71
5 years 5.65
Extreme 5.65
71.71
10 years 5.65
Extreme 5.65
71.71
Manager TitleAgeSince
Chief Executive Officer 67 01/06/2017
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 01/01/2021
Director TitleAgeSince
Director/Board Member 64 18/03/2021
Director/Board Member 55 18/03/2021
Director/Board Member 40 01/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/26 Don

Founder

-123,840 0.2061%
08/07/26 Exercice

Founder

14,000 0.0233%
02/06/26 Sell

Executive/Senior Manager

-4,059 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+3.42%+0.35%-36.89%+186.71% 1.02B
-3.10%-4.19%+32.67%+59.47% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.46%+11.00%+44.65% 32.71B
+1.11%+15.18%+60.27%+49.33% 26.5B
+3.18%-6.72%+25.35%-8.75% 24.01B
Average +0.36%-0.12%+37.45%+157.79% 38.43B
Weighted average by Cap. -0.34%-0.58%+42.31%+153.51%

Financials

2026 *2027 *
Net sales 29.42M 26.41M 24.38M 22.11M 41.33M 2.79B 41.84M 292M 116M 1.46B 110M 108M 4.65B 8.1M 7.27M 6.71M 6.09M 11.38M 769M 11.51M 80.47M 31.96M 403M 30.4M 29.75M 1.28B
Net income -107M -96.18M -88.81M -80.53M -151M -10.18B -152M -1.06B -423M -5.34B -402M -394M -16.92B -178M -159M -147M -134M -250M -16.88B -253M -1.77B -701M -8.85B -667M -653M -28.06B
Net Debt -899M -807M -745M -676M -1.26B -85.39B -1.28B -8.93B -3.55B -44.76B -3.37B -3.3B -142B -750M -673M -621M -563M -1.05B -71.21B -1.07B -7.45B -2.96B -37.32B -2.81B -2.75B -118B
Projected Income Statement - Annual - Janux Therapeutics, Inc.
Logo Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Employees
113
Date Price Change Volume
27/10/26 $17.26 +3.42% 687,228
26/10/26 $16.69 +0.18% 379,225
23/10/26 $16.66 -2.34% 378,883
22/10/26 $17.06 +0.77% 514,248
21/10/26 $16.93 -1.57% 587,432
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Janux Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
17.26USD
Average target price
33.81USD
Spread / Average Target
+95.90%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Janux Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. JANX Stock